Abstract:Minimal residual disease (MRD) is of major importance in onco-hematology, particularly in acute myeloid leukemia (AML). MRD measures the amount of leukemia cells remaining in a patient after treatment, and is an essential tool for disease monitoring, relapse prognosis, and guiding treatment decisions. Patients with a negative MRD tend to have superior disease-free and overall survival rates. Considerable effort has been made to standardize MRD practices. A variety of techniques, including flow cytometry and molecular methods, are used to assess MRD, each with distinct strengths and weaknesses. MRD is recognized not only as a predictive biomarker, but also as a prognostic tool and marker of treatment efficacy. Expected advances in MRD assessment encompass molecular techniques such as NGS and digital PCR, as well as optimization strategies such as unsupervised flow cytometry analysis and leukemic stem cell monitoring. At present, there is no perfect method for measuring MRD, and significant advances are expected in the future to fully integrate MRD assessment into the management of AML patients.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the evaluation and monitoring of minimal residual disease (MRD) in acute myeloid leukemia (AML). Specifically, the paper focuses on the following aspects: 1. **Definition and Importance**: The paper first defines MRD and emphasizes its importance in AML. MRD refers to the amount of leukemia cells remaining in patients after treatment and is an important tool for disease monitoring, relapse prognosis, and guiding treatment decisions. Patients with negative MRD usually have better disease - free survival rates and overall survival rates. 2. **Standardization Efforts**: Internationally, a great deal of effort has been made to standardize MRD detection methods, positive thresholds, detection frequencies, and the selection of biological materials. These efforts have led to the release of two consensus documents, namely the guidelines on MRD evaluation in AML and AML diagnosis and treatment released by the European Leukemia Network (ELN) in 2021 and 2022 respectively. 3. **Comparison of Different Technologies**: The paper discusses in detail a variety of techniques for evaluating MRD, including flow cytometry (MFC), quantitative polymerase chain reaction (qPCR), next - generation sequencing (NGS), and digital polymerase chain reaction (dPCR). Each technique has its advantages and limitations, and the paper explores the comparison between these techniques and their applications in clinical practice. 4. **Clinical Trials and Clinical Roles**: The paper summarizes the role of MRD in clinical trials, including as a predictive marker for relapse risk, a prognostic tool for survival, a marker for treatment efficacy, and a surrogate endpoint in clinical trials. Although MRD shows important value in these aspects, there is currently no unified gold - standard evaluation method. 5. **Current Guidelines**: The paper introduces the ELN updates in 2021 and 2022, clarifying that MFC and qPCR are the preferred techniques for monitoring MRD in current clinical practice. At the same time, the paper also mentions new concepts of remission and relapse, incorporating MRD results into them. 6. **Future Prospects**: The paper points out that currently no single technique can perfectly evaluate MRD, and future research needs to further optimize existing techniques and methods to better integrate MRD evaluation into the management of AML patients. In summary, this paper aims to comprehensively summarize and explore the evaluation methods of MRD in AML and their applications in clinical practice, providing guidance for future standardization and optimization.

Old and New Concepts

Detection methods and prognosis implications of measurable residual disease in acute myeloid leukemia

Role of minimal residual disease in the management of acute myeloid leukemia-a case-based discussion

Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making

Measurable Residual Disease Detection in Acute Myeloid Leukemia: Current Challenges and Future Directions

MRD in ALL: Optimization and Innovations

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia

Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development

Achieving MRD negativity in AML: how important is this and how do we get there?

MRD Tailored Therapy in AML: What We Have Learned So Far

Molecular MRD Assessment in Acute Myeloid Leukemias

Measurable Residual Disease in High-Risk Acute Myeloid Leukemia

Optimizing Molecular Minimal Residual Disease Analysis in Adult Acute Lymphoblastic Leukemia

Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: adapting Pre-MEASURE to clinical practice

Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients

Measurable residual disease in hematopoietic stem cell transplantation-eligible patients with acute myeloid leukemia: clinical significance and promising therapeutic strategies

Measurable (Minimal) Residual Disease in Myelodysplastic Neoplasms (MDS): Current State and Perspectives

Abstract 2793: Minimal residual disease (MRD) as a predictive biomarker/endpoint for novel drug development

MRD in Acute Leukemias: Lessons Learned from Acute Promyelocytic Leukemia

Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia